BUHLMANN Laboratories AG Receives FDA Clearance for Its fCAL[R] turbo Automated, Random Access Calprotectin Test.
The use of a non-invasive inflammation bio-marker such as calprotectin is crucial with the increasing prevalence of gastrointestinal disease and the challenges of traditional treatment pathways. The 2018 clinical guidelines of the American College of Gastroenterology (ACG) strongly recommends fCAL as helpful test that should be considered as an aid to differentiate the presence of IBD from IBS. As a result, major health insurance companies have started covering calprotectin testing (CPT: 83993).
Due to the quality performance and high capacity of BUHLMANN fCAL[R] turbo, this assay can be applied economically in low/mid volume laboratories as well as in very high volume reference labs. Testing turnaround time can be reduced significantly not only compared to the existing ELISA methods but also to other automated, random access calprotectin assays. BUHLMANN fCAL[R] turbo is a real milestone for efficient handling of increasing workloads in the laboratory being the highest throughput calprotectin assay with the fastest time-to-first-result in the U.S. market.
Doug Olson, CEO of BUHLMANN Diagnostics Corp commented, "We are very pleased to launch this robust, high quality assay to assist physicians in evaluating patients in a timely manner and to help laboratories across North America to meet the increasing demand for calprotectin testing. This test provides a high throughput option to our FDA cleared BUHLMANN fCAL[R] ELISA, providing flexibility in testing options. Most importantly, this assay portfolio offers consistency - no matter which assay you choose, results are reliable, accurate, and consistent across the platforms."
In a multi-site clinical study, BUHLMANN fCAL[R] turbo demonstrated excellent precision and reproducibility, while confirming that this test is a valuable diagnostic aid in the diagnosis of IBD and in the discrimination between IBD and IBS.
Visit www.buhlmannlabs.com to learn more about this assay, and overall performance.
About BUHLMANN Laboratories AG
Founded in 1976, BUHLMANN Laboratories AG has continued to focus on growing a product portfolio of in vitro diagnostics and research markets. BUHLMANN is known for outstanding product quality, providing excellent after-sales services, and delivering remarkable scientific innovations. BUHLMANN offers the broadest range of calprotectin products as well as a selection of unique, high-quality assays such as the BUHLMANN Flow CAST[R] product group for Basophil Activation Testing, the BUHLMANN GanglioCombi[TM] products for neuroimmunology, and a variety of Melatonin Assays.
About BUHLMANN Diagnostics Corp (BDC)
BUHLMANN Diagnostics Corp (BDC) is the North American affiliate of BUHLMANN Laboratories AG, the worldwide provider of ELISA kits, RIA kits, lateral flow and flow cytometry assays. Located in Southern New Hampshire, BDC has a highly experienced team who represent a breadth of experience in serving both clinical and basic science research laboratories.
About BUHLMANN Calprotectin Product Line
The calprotectin portfolio consists of the BUHLMANN fCAL[R] ELISA (FDA 510(k) cleared), BUHLMANN fCAL[R] turbo (FDA 510(k) cleared) for testing on most clinical chemistry analyzers (RUO in the US), Quantum Blue[R] fCAL Rapid Test (RUO in the US), and IBDoc[R], the first and only Health Canada Licensed home-testing application for fecal calprotectin in IBD patients (IBDoc[R] not available for sale in the US).
BUHLMANN Diagnostics Corp
Contact via Email
Read the full story here: https://www.pr.com/press-release/788419
|Printer friendly Cite/link Email Feedback|
|Publication:||PR.com (Press Releases)|
|Date:||Jun 27, 2019|
|Previous Article:||Best Western International Endorses FortisPay.|
|Next Article:||National LTC Pharmacy Advocacy Group Asks CMS to Release "Summary Data" on PBM Medicare Spread Pricing Activity.|